Targegen, Inc.

Dart Neuroscience, (cayman) Ltd.

V & P Scientific, Inc.

Dart Neuroscience, LLC

Joel Renick

Jianguo Cao

Chi Ching Mak

Richard Soll

Glenn Noronha

Ved Prakash Pathak

John Hood

Elena Dneprovskaia

Wolfgang J Wrasidlo

Richard M Soll

Binqi Zeng

Andrew McPherson

Colleen Gritzen

Daniel L Lohse

Alan P Kaplan

Mi Chen

Brett C Bookser

Andrew Richard Hudson

Varsha Gupta

Jillian Basinger

Vincent Santora

Ute Splittgerber

Ningning Zhao

Xianchang Gong

James Na

Kathy Barrett

Patrick H Cleveland

Graeme Freestone

DeMichael Chung

Kristi K Myers

Alan J Loi

John E Chavez

Christopher A Angelo

Christopher P W Hickman

Natalie A Knuth

Andrew Mc Pherson

Daniel Lohse

Provided herein are apparatuses and systems for mixing liquids and suspensions that include vessels with structures that improve mixing while not contacting liquid delivery components. The apparatuses and systems can include a motor drive that allows speed and directional control of rotation of the vessel. The apparatuses and systems can include one or more magnets for separating magnetic beads in a suspension. Also provided are methods using said apparatuses and systems for mixing and separation processes.

Spinning vessel systems and methods for mixing, suspending particulates, aliquoting, washing magnetic beads, and concentrating analytes

The invention provides a chemical entity of Formula (I) wherein R, R, R, R, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence. 

Substituted azetidinyl compounds as GlyT1 inhibitors

The invention provides a chemical entity of Formula (I), wherein R, R, R, R, Rand X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence. 

Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors

The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAreceptor and negatively modulating the &#x3b1;5 subtype of GABA, and use of the compound of formula I in the manufacture of a medicament for the treatment of GABAreceptor associated disorders. The invention further provides a method of modulation of one or more GABAsubtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

Therapeutic 5,6,5-tricyclic analogs

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. 

Bi-aryl meta-pyrimidine inhibitors of kinases

The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases. 

Benzotriazine inhibitors of kinases

Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases. 

2-amino&#x2014;5-substituted pyrimidine inhibitors

Growing community of inventors

San Diego, CA, United States of America

Joel Renick